glipizide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 1301 29094-61-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • glypidizine
  • glidiazinamide
  • K 4024
  • K-4024
  • K4024
  • glipizide
  • dipazide
  • glibenese
  • glipizid
  • glucotrol
  • glucozide
  • glupizide
  • glydiazinamide
  • melizide
  • napizide
  • sucrazide
An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.
  • Molecular weight: 445.54
  • Formula: C21H27N5O4S
  • CLOGP: 2.57
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 130.15
  • ALOGS: -4.43
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.96 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.16 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.56 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.30 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 8, 1984 FDA PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood glucose increased 624.24 11.63 466 32153 71547 46581896
Hypoglycaemia 340.56 11.63 291 32328 54058 46599385
Cardiac failure congestive 259.61 11.63 320 32299 91430 46562013
Blood glucose decreased 250.23 11.63 159 32460 18733 46634710
Coronary artery disease 158.82 11.63 154 32465 33598 46619845
Myocardial infarction 152.86 11.63 257 32362 97271 46556172
Diabetes mellitus inadequate control 128.85 11.63 92 32527 13122 46640321
Product residue present 113.28 11.63 55 32564 3827 46649616
Rheumatoid arthritis 97.48 11.63 24 32595 240191 46413252
Cerebrovascular accident 89.83 11.63 210 32409 100829 46552614
Glycosylated haemoglobin increased 82.16 11.63 65 32554 10811 46642632
Blood glucose fluctuation 78.63 11.63 44 32575 4102 46649341
Pancreatitis 73.68 11.63 119 32500 43508 46609935
Diabetes mellitus 68.03 11.63 124 32495 49941 46603502
Product complaint 60.27 11.63 57 32562 12044 46641399
Exposure during pregnancy 57.10 11.63 5 32614 108207 46545236
Blood glucose abnormal 46.41 11.63 38 32581 6634 46646809
Hyperglycaemia 45.29 11.63 85 32534 34986 46618457
Off label use 45.09 11.63 127 32492 379714 46273729
Hypoglycaemic coma 42.61 11.63 25 32594 2549 46650894
Type 2 diabetes mellitus 40.27 11.63 59 32560 19816 46633627
Drug ineffective 38.02 11.63 298 32321 677540 45975903
Mental status changes 35.82 11.63 81 32538 38007 46615436
Renal failure 35.24 11.63 165 32454 113429 46540014
Ischaemic cardiomyopathy 34.62 11.63 22 32597 2588 46650855
Treatment failure 34.54 11.63 11 32608 93076 46560367
Infusion related reaction 34.09 11.63 14 32605 101194 46552249
Pyrexia 33.49 11.63 128 32491 348674 46304769
Cutaneous T-cell dyscrasia 32.83 11.63 8 32611 62 46653381
Chest pain 30.33 11.63 219 32400 176105 46477338
Drug intolerance 29.06 11.63 36 32583 147013 46506430
Nodular rash 28.67 11.63 9 32610 190 46653253
Heart injury 28.65 11.63 15 32604 1224 46652219
C-reactive protein increased 27.65 11.63 4 32615 58586 46594857
Diabetic neuropathy 27.24 11.63 22 32597 3767 46649676
Diabetic ketoacidosis 27.16 11.63 47 32572 18163 46635280
Oedema peripheral 26.68 11.63 197 32422 159509 46493934
General physical health deterioration 26.58 11.63 25 32594 115744 46537699
Product dose omission issue 26.53 11.63 205 32414 168315 46485128
Acute myocardial infarction 24.75 11.63 63 32556 31861 46621582
Myocardial ischaemia 24.61 11.63 37 32582 12712 46640731
Drug abuse 24.41 11.63 7 32612 63401 46590042
Weight decreased 23.61 11.63 238 32381 210611 46442832
Stool analysis abnormal 23.35 11.63 6 32613 59 46653384
Cardiac disorder 22.80 11.63 75 32544 43783 46609660
Gout 21.98 11.63 33 32586 11323 46642120
Asthenia 21.69 11.63 321 32298 310754 46342689
Lower respiratory tract infection 21.35 11.63 6 32613 55083 46598360
Suicide attempt 21.32 11.63 6 32613 55030 46598413
Transient ischaemic attack 21.20 11.63 63 32556 34840 46618603
Pernicious anaemia 20.68 11.63 10 32609 689 46652754
Dehydration 20.28 11.63 185 32434 159355 46494088
Pancreatitis haemorrhagic 19.43 11.63 7 32612 228 46653215
Thrombosis 19.28 11.63 84 32535 55985 46597458
Pancreatitis acute 19.19 11.63 49 32570 24823 46628620
Ventricular hypertrophy 19.05 11.63 18 32601 3796 46649647
Acute kidney injury 18.68 11.63 249 32370 235606 46417837
Abortion spontaneous 18.38 11.63 4 32615 43642 46609801
Musculoskeletal stiffness 18.31 11.63 25 32594 97968 46555475
Synovitis 18.18 11.63 10 32609 61065 46592378
Chronic obstructive pulmonary disease 18.06 11.63 84 32535 57549 46595894
Ventricular dysfunction 17.37 11.63 15 32604 2817 46650626
Urinary tract infection 17.22 11.63 232 32387 220034 46433409
Joint swelling 17.18 11.63 59 32560 166014 46487429
Injection site nodule 17.01 11.63 16 32603 3355 46650088
Hypoacusis 16.90 11.63 42 32577 20927 46632516
Leukopenia 16.59 11.63 14 32605 68329 46585114
Coronary artery occlusion 16.33 11.63 24 32595 8078 46645365
Cardiovascular disorder 16.30 11.63 30 32589 12157 46641286
Systemic lupus erythematosus 16.26 11.63 13 32606 65167 46588276
Renal injury 16.06 11.63 26 32593 9515 46643928
Chronic kidney disease 15.42 11.63 63 32556 40808 46612635
Acute coronary syndrome 14.78 11.63 26 32593 10178 46643265
Treatment noncompliance 14.71 11.63 50 32569 29681 46623762
Dilatation atrial 14.41 11.63 12 32607 2145 46651298
Adenocarcinoma pancreas 13.58 11.63 9 32610 1137 46652306
Lactic acidosis 13.38 11.63 53 32566 33856 46619587
Product use issue 13.24 11.63 29 32590 94615 46558828
Febrile neutropenia 13.24 11.63 29 32590 94598 46558845
Electrocardiogram QT prolonged 13.10 11.63 10 32609 51315 46602128
Accidental poisoning 13.07 11.63 7 32612 598 46652845
Dizziness 12.89 11.63 320 32299 340094 46313349
Hyperinsulinaemia 12.85 11.63 4 32615 82 46653361
Angioedema 12.81 11.63 58 32561 39284 46614159
Blood potassium increased 12.65 11.63 33 32586 16934 46636509
Pancreatic carcinoma 12.61 11.63 19 32600 6538 46646905
Angina unstable 11.94 11.63 20 32599 7528 46645915
Hepatocellular injury 11.85 11.63 3 32616 29519 46623924
Nausea 11.65 11.63 589 32030 686865 45966578
Rhabdomyolysis 11.63 11.63 59 32560 41850 46611593

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hypoglycaemia 611.14 11.54 493 34507 50488 29866990
Blood glucose increased 490.37 11.54 472 34528 61058 29856420
Cardiac failure congestive 264.21 11.54 403 34597 84004 29833474
Myocardial infarction 224.06 11.54 469 34531 125156 29792322
Coronary artery disease 169.11 11.54 247 34753 49465 29868013
Blood glucose decreased 147.09 11.54 122 34878 12931 29904547
Completed suicide 113.81 11.54 313 34687 99179 29818299
Glycosylated haemoglobin increased 95.22 11.54 83 34917 9408 29908070
Drug abuse 76.25 11.54 5 34995 82067 29835411
Cerebrovascular accident 71.22 11.54 237 34763 83240 29834238
Off label use 67.10 11.54 118 34882 249172 29668306
Pancreatitis 57.67 11.54 130 34870 36360 29881118
Product complaint 56.68 11.54 50 34950 5756 29911722
Blood glucose abnormal 54.79 11.54 47 34953 5212 29912266
Diabetes mellitus inadequate control 45.64 11.54 65 34935 12697 29904781
Product residue present 45.54 11.54 32 34968 2646 29914832
Myocardial ischaemia 42.23 11.54 74 34926 17243 29900235
Mental status changes 38.72 11.54 113 34887 36966 29880512
Injury 37.24 11.54 80 34920 21651 29895827
Cardiac disorder 36.44 11.54 116 34884 39777 29877701
General physical health deterioration 36.21 11.54 38 34962 99906 29817572
Ischaemic cardiomyopathy 35.10 11.54 40 34960 6257 29911221
Bladder cancer 34.99 11.54 48 34952 9054 29908424
C-reactive protein increased 34.24 11.54 5 34995 43468 29874010
Interstitial lung disease 33.79 11.54 14 34986 60183 29857295
Heart injury 33.35 11.54 21 34979 1445 29916033
Febrile neutropenia 32.90 11.54 46 34954 106647 29810831
Blood glucose fluctuation 32.72 11.54 30 34970 3631 29913847
Pyrexia 30.17 11.54 211 34789 294278 29623200
Spur cell anaemia 29.84 11.54 8 34992 53 29917425
Cardiovascular disorder 29.60 11.54 49 34951 10903 29906575
Diabetic neuropathy 28.87 11.54 29 34971 3930 29913548
Myasthenic syndrome 28.67 11.54 12 34988 347 29917131
Diabetes mellitus 28.11 11.54 110 34890 41755 29875723
Product use in unapproved indication 27.85 11.54 27 34973 73666 29843812
Neutropenia 23.90 11.54 74 34926 128466 29789012
Emotional distress 22.51 11.54 54 34946 15711 29901767
Hypophagia 22.47 11.54 67 34933 22169 29895309
Arteriosclerosis 22.26 11.54 43 34957 10790 29906688
Diabetic ketoacidosis 20.97 11.54 53 34947 15933 29901545
Transient ischaemic attack 20.96 11.54 71 34929 25129 29892349
Pancreatitis acute 20.16 11.54 71 34929 25624 29891854
Arteriosclerosis coronary artery 20.13 11.54 42 34958 11134 29906344
Type 2 diabetes mellitus 19.82 11.54 47 34953 13575 29903903
Asthenia 19.21 11.54 364 34636 220926 29696552
Angina unstable 18.48 11.54 43 34957 12267 29905211
Gastrointestinal mucosal necrosis 18.30 11.54 7 34993 159 29917319
Product dose omission issue 17.62 11.54 174 34826 91457 29826021
Interstitial granulomatous dermatitis 17.52 11.54 7 34993 179 29917299
Leukopenia 17.51 11.54 24 34976 56135 29861343
Alanine aminotransferase increased 17.44 11.54 38 34962 74238 29843240
Hyperglycaemia 17.14 11.54 84 34916 35116 29882362
Acute myocardial infarction 16.98 11.54 113 34887 52826 29864652
Agranulocytosis 16.21 11.54 3 34997 21939 29895539
Glycosylated haemoglobin decreased 15.94 11.54 8 34992 354 29917124
Cytomegalovirus infection 15.94 11.54 4 34996 23670 29893808
Weight decreased 15.85 11.54 256 34744 150665 29766813
Cardiomyopathy 15.65 11.54 46 34954 15097 29902381
Poor quality product administered 15.55 11.54 14 34986 1655 29915823
Neutrophil count decreased 15.52 11.54 16 34984 42438 29875040
Hyphaema 15.04 11.54 8 34992 400 29917078
Unresponsive to stimuli 15.04 11.54 66 34934 26353 29891125
Pancreatic carcinoma 14.76 11.54 30 34970 7807 29909671
Anhedonia 14.55 11.54 31 34969 8338 29909140
Rheumatoid arthritis 14.53 11.54 16 34984 41181 29876297
Renal injury 14.47 11.54 38 34962 11691 29905787
Aspartate aminotransferase increased 14.44 11.54 33 34967 63389 29854089
Suicide attempt 14.38 11.54 13 34987 36684 29880794
Drug resistance 14.35 11.54 3 34997 20130 29897348
Altered state of consciousness 14.14 11.54 3 34997 19916 29897562
Treatment failure 13.93 11.54 12 34988 34667 29882811
Peripheral vascular disorder 13.63 11.54 23 34977 5196 29912282
Human anaplasmosis 13.04 11.54 4 34996 45 29917433
Hepatic function abnormal 13.00 11.54 18 34982 41927 29875551
Drug ineffective 12.71 11.54 302 34698 340085 29577393
Hepatocellular injury 12.64 11.54 7 34993 25464 29892014
Bone marrow failure 12.34 11.54 10 34990 29775 29887703
Lower respiratory tract infection 12.33 11.54 8 34992 26706 29890772
Blood bilirubin increased 12.09 11.54 15 34985 36621 29880857
Electrocardiogram ST-T change 11.94 11.54 8 34992 612 29916866
Occult blood positive 11.78 11.54 18 34982 3742 29913736
Diverticulum 11.78 11.54 25 34975 6708 29910770
Thrombocytopenia 11.73 11.54 103 34897 136941 29780537

Pharmacologic Action:

SourceCodeDescription
ATC A10BB07 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Sulfonylureas
FDA CS M0020795 Sulfonylurea Compounds
FDA EPC N0000175608 Sulfonylurea
CHEBI has role CHEBI:35526 hypoglycemic drug
CHEBI has role CHEBI:77194 pantothenate kinase (phosphorylating) inhibitors
CHEBI has role CHEBI:90415 insulin secretagogues
MeSH PA D007004 Hypoglycemic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Alcoholism contraindication 7200002
Asthenia contraindication 13791008
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Infectious disease contraindication 40733004
Hepatic porphyria contraindication 55056006 DOID:3133
Ketoacidosis contraindication 56051008
Metabolic acidosis contraindication 59455009
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Cobalamin deficiency contraindication 190634004
Decompensated cardiac failure contraindication 195111005
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Severe diarrhea contraindication 409587002
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Prolonged-Severe Nausea and Vomiting contraindication
Radiography with IV Iodinated Contrast Agent contraindication
Severe Hypoxemia contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.31 acidic
pKa2 11.71 acidic
pKa3 12.9 acidic
pKa4 3.19 Basic
pKa5 0.2 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER Kd 9.10 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
4018508 VUID
N0000146830 NUI
D00335 KEGG_DRUG
4018508 VANDF
C0591568 UMLSCUI
CHEBI:5384 CHEBI
CHEMBL1073 ChEMBL_ID
DB01067 DRUGBANK_ID
D005913 MESH_DESCRIPTOR_UI
3478 PUBCHEM_CID
6821 IUPHAR_LIGAND_ID
3090 INN_ID
X7WDT95N5C UNII
151822 RXNORM
4783 MMSL
574 MMSL
595 MMSL
d00246 MMSL
000913 NDDF
26124005 SNOMEDCT_US
387143009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0170 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 27 sections
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0174 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 27 sections
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-0178 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-1550 TABLET, EXTENDED RELEASE 5 mg ORAL NDA 27 sections
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-1560 TABLET, EXTENDED RELEASE 10 mg ORAL NDA 27 sections
Glucotrol XL HUMAN PRESCRIPTION DRUG LABEL 1 0049-1620 TABLET, EXTENDED RELEASE 2.50 mg ORAL NDA 27 sections
Glucotrol HUMAN PRESCRIPTION DRUG LABEL 1 0049-4110 TABLET 5 mg ORAL NDA 25 sections
Glucotrol HUMAN PRESCRIPTION DRUG LABEL 1 0049-4120 TABLET 10 mg ORAL NDA 25 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7455 TABLET, FILM COATED 2.50 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7456 TABLET, FILM COATED 2.50 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7457 TABLET, FILM COATED 5 mg ORAL ANDA 27 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0378-1105 TABLET 5 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0378-1110 TABLET 10 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0591-0460 TABLET 5 mg ORAL ANDA 13 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0591-0461 TABLET 10 mg ORAL ANDA 13 sections
GlipizideER HUMAN PRESCRIPTION DRUG LABEL 1 0591-0844 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL ANDA 26 sections
GlipizideER HUMAN PRESCRIPTION DRUG LABEL 1 0591-0845 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 26 sections
GlipizideER HUMAN PRESCRIPTION DRUG LABEL 1 0591-0900 TABLET, FILM COATED, EXTENDED RELEASE 2.50 mg ORAL ANDA 26 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-7968 TABLET 5 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0615-7969 TABLET 10 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 0904-6637 TABLET 5 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10370-745 TABLET, FILM COATED, EXTENDED RELEASE 5 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10370-746 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL ANDA 25 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10544-192 TABLET 10 mg ORAL ANDA 12 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10544-193 TABLET 5 mg ORAL ANDA 12 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10544-220 TABLET 5 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 10544-221 TABLET 10 mg ORAL ANDA 20 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 12634-729 TABLET 5 mg ORAL ANDA 26 sections
Glipizide HUMAN PRESCRIPTION DRUG LABEL 1 12634-790 TABLET 10 mg ORAL ANDA 26 sections
GLIPIZIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-286 TABLET 5 mg ORAL ANDA 12 sections